Abstract
Gene therapy, the expression in cells of genetic material that has therapeutic activity, holds great promise for the treatment of a number of human diseases. A gene delivery vehicle, or vector, that may be of viral or non-viral origin, is generally used to carry the genetic material. Viral vectors have been developed that exclude immunogenic genes while taking advantage of the genes responsible for proficient integration of the viral genome into that of the host. In this way, viral vectors improve the probability of long-term expression of the therapeutic gene, whereas non-viral vectors, that are not as efficient at introducing and maintaining foreign gene expression, have the advantage of being non-pathogenic and non-immunogenic. Although thousands of patients have been involved in clinical trials for gene therapy, using hundreds of different protocols, true success has been limited. A major limitation of gene therapy approaches, especially when non-viral vectors are used, is the poor efficiency of DNA delivery to the nucleus; a crucial step to ensure ultimate expression of the therapeutic gene product. Here we review existing gene delivery approaches and, in particular, explore the possibility of enhancing non-viral gene delivery to the nucleus by incorporating specific nuclear targeting sequences in vectors, using a range of different strategies.
Current Drug Targets
Title: Gene Therapy: Optimising DNA Delivery to the Nucleus
Volume: 2 Issue: 4
Author(s): Melanie Johnson-Saliba and David A. Jans
Affiliation:
Abstract: Gene therapy, the expression in cells of genetic material that has therapeutic activity, holds great promise for the treatment of a number of human diseases. A gene delivery vehicle, or vector, that may be of viral or non-viral origin, is generally used to carry the genetic material. Viral vectors have been developed that exclude immunogenic genes while taking advantage of the genes responsible for proficient integration of the viral genome into that of the host. In this way, viral vectors improve the probability of long-term expression of the therapeutic gene, whereas non-viral vectors, that are not as efficient at introducing and maintaining foreign gene expression, have the advantage of being non-pathogenic and non-immunogenic. Although thousands of patients have been involved in clinical trials for gene therapy, using hundreds of different protocols, true success has been limited. A major limitation of gene therapy approaches, especially when non-viral vectors are used, is the poor efficiency of DNA delivery to the nucleus; a crucial step to ensure ultimate expression of the therapeutic gene product. Here we review existing gene delivery approaches and, in particular, explore the possibility of enhancing non-viral gene delivery to the nucleus by incorporating specific nuclear targeting sequences in vectors, using a range of different strategies.
Export Options
About this article
Cite this article as:
Johnson-Saliba Melanie and Jans A. David, Gene Therapy: Optimising DNA Delivery to the Nucleus, Current Drug Targets 2001; 2 (4) . https://dx.doi.org/10.2174/1389450013348245
DOI https://dx.doi.org/10.2174/1389450013348245 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
Drug-Targeted Approach with Polymer Nanocomposites for Improved Therapeutics
Polymer nanocomposites have been recognized as an advanced and cutting-edge technique in drug targeting administration. These materials combine the unique features of nanoparticles with the adaptability of polymers to produce highly personalized drug administration devices. Integrating nanoparticles containing pharmaceuticals into a polymer matrix enables researchers to regulate the rates at ...read more
RNA Molecules in the Treatment of Human Diseases
Messenger and non-coding RNAs, including long and small transcripts, are mediators of gene expression. Gene expression at the RNA level shows significant aberrations in human diseases, including cancer, leukemia, lymphoma, cardiovascular diseases, and neurological disorders. Human transcripts serve either as biomarkers of diagnosis, prognosis, prediction of treatment response and/or therapy ...read more
![](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Antineoplastic Activity of Monocrotaline Against Hepatocellular Carcinoma
Anti-Cancer Agents in Medicinal Chemistry Human Neural Stem and Progenitor Cells: In Vitro and In Vivo Properties, and Potential for Gene Therapy and Cell Replacement in the CNS
Current Gene Therapy Recent Advancements in Fuzzy C-means Based Techniques for Brain MRI Segmentation
Current Medical Imaging Traditional Chinese Medicine Remedy to Jury: The Pharmacological Basis for the Use of Shikonin as an Anticancer Therapy
Current Medicinal Chemistry Mitochondrial Dysfunction in Gliomas: Pharmacotherapeutic Potential of Natural Compounds
Current Neuropharmacology Cryptotanshinone Induces Pro-death Autophagy through JNK Signaling Mediated by Reactive Oxygen Species Generation in Lung Cancer Cells
Anti-Cancer Agents in Medicinal Chemistry Research Progress in Tumor Diagnosis Based on Raman Spectroscopy
Current Medical Imaging Multilevel Pharmacological Effects of Antipsychotics in Potential Glioblastoma Treatment
Current Topics in Medicinal Chemistry MR Spectroscopy in Metabolic Profiling Studies of Stem Cells
Current Medical Imaging A Novel Highly Selective Cannabinoid CB2 Agonist Reduces in vitro Growth and TGF-beta Release of Human Glial Cell Tumors
Central Nervous System Agents in Medicinal Chemistry The Therapeutic Potential of Toll-Like Receptor 7 Stimulation in Asthma
Inflammation & Allergy - Drug Targets (Discontinued) Anti-Cancer Targeting Telomerase Inhibitors: β-Rubromycin and Oleic Acid
Mini-Reviews in Medicinal Chemistry Molecular Based Drug Targets for Idiopathic Pulmonary Fibrosis
Current Respiratory Medicine Reviews Recent Patents, Formulation and Characterization of Nanoliposomes
Recent Patents on Drug Delivery & Formulation Polyisoprenylated Cysteinyl Amide Inhibitors: A Novel Approach to Controlling Cancers with Hyperactive Growth Signaling
Current Medicinal Chemistry CB1 Cannabinoid Receptors and their Associated Proteins
Current Medicinal Chemistry Effect of MRJF4 on C6 Glioma Cells Proliferation and Migration
Central Nervous System Agents in Medicinal Chemistry Nitric Oxide and Dietary Factors: Part III Minerals, Vitamins and Other Dietary and Lifestyle Factors
Vascular Disease Prevention (Discontinued) Sanguinarine: A Double-Edged Sword of Anticancer and Carcinogenesis and Its Future Application Prospect
Anti-Cancer Agents in Medicinal Chemistry Targeting Ion Channels for New Strategies in Cancer Diagnosis and Therapy
Current Clinical Pharmacology